• ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

  • May 30 2024
  • Duración: 13 m
  • Podcast

ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference Por arte de portada

ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Chris Barden, a co-managing partner at MPM Bioimpact who manages the firm’s Bioimpact Equities and Oncology Impact funds, shares her insights into the upcoming American Society of Clinical Oncology (ASCO) conference in Chicago. She talks about the major trends in oncology, including development of antibody drug conjugates, which is currently the hottest area in cancer treatment. Another highlight she expects from ASCO will be development in radiotherapy treatments, particularly in prostate cancer. Bardon provides a guide for attendees to use in setting their schedules for the year’s biggest cancer conference and what to watch for in the future.
    Más Menos
activate_primeday_promo_in_buybox_DT
Ciencias Biológicas
Más Menos

Lo que los oyentes dicen sobre ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles